AAV 介导的基因治疗在 Cockayne 综合征小鼠模型中实现表型改善
AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome
Cockayne 综合征是一种因 ERCC8/CSA 基因突变导致的隐性遗传病，表现为光敏、生长障碍、寿命缩短和中枢神经系统进行性退化，目前无有效治疗。研究者设计携带人 CSA 基因的 AAV9 载体，在新生 Csa-/- Xpa-/- 小鼠中经脑室内注射。治疗显著延长了小鼠寿命，人 CSA 在脑和心脏广泛分布，未见载体相关毒性；但仍观察到髓鞘化不足、星形胶质细胞和小胶质细胞增生等神经病理改变，以及肝脏转录组异常。该结果支持向人体临床转化，但安全性问题仍需进一步解决。
为什么推荐给您：首次在Cockayne综合征模型中用AAV基因治疗取得寿命与表型改善，具备临床转化前景的新平台证据
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Cockayne syndrome (CS) is an autosomal recessive, progressive developmental and neurodegenerative disease. Approximately 30% of cases are caused by mutations in the ERCC8/CSA gene. Patients with CS present with cutaneous photosensitivity, growth failure, shorter life span, and a progressive degeneration of the central nervous system. Loss-of-function mutations in CSA result in deficiencies in transcription-coupled nucleotide excision repair. Currently, no therapies are available for these patients. Adeno-associated virus-mediated (AAV-mediated) gene therapy offers an opportunity to address this unmet need. We designed an AAV vector encoding human CSA under a ubiquitous promoter. We tested the therapeutic efficacy of this AAV9-CSA vector by neonatal intracerebroventricular injection in the Csa-/- Xpa-/- mouse model. Treatment with AAV9-CSA resulted in a significant increase in life span, and broad distribution of human CSA in the brain and heart, without evidence of vector-related toxicity. Despite clear therapeutic benefit, we also observed neuroradiological abnormalities, and neuropathologic alterations, including hypomyelination, astrocytosis, and microgliosis, as well as likely life-limiting transcriptomic alterations in liver at endpoint. Nonetheless, the success of these experiments paves the way for clinical translation of an AAV gene therapy for patients with CS into humans.